Sequential action of Ets-1 and Sp1 in the activation of the human β-1,4-galactosyltransferase v gene involved in abnormal glycosylation characteristic of cancer cells

\Malignant transformation is associated with increased gene expression of beta-1,4-galactosyltransferase (beta-1,4-GaIT) V, which contributes to the biosynthesis of highly branched N-linked oligosaccharides characteristic of cancer cells. Our previous study showed that expression of the human beta-1,4-GaIT V gene is regulated by Spl (Sato, T., and Furukawa, K. (2004) J. BioL Chem. 279, 39574-39583), and a subsequent study showed that the gene expression is also activated by Ets-1, a product of the oncogene (Sato, T., and Furukawa, K. (2005) Glycoconj. J. 22, 365). Herein we report the mechanism of beta-1,4-GaIT V gene activation by these transcription factors. The gene expression and promoter activity of beta-1,4-GaIT V increased when the ets-1 cDNA was transfected into A549 cells, which contain a small amount of Ets-1, but decreased dramatically when the dominant-negative ets-1 cDNA was transfected into HepG2 cells, which contain a large amount of Ets-1. Luciferase assays using deletion constructs of the beta-1,4-GaIT V gene promoter showed that promoter region - 116 to + 22 is critical for the transcriptional activation of the gene by Ets-1. Despite the presence of one Ets-1-binding site, which overlapped the Sp1-binding site, electrophoretic mobility shift assays showed that the region bound preferentially to Spl rather than to Ets-1. To solve this problem, we examined the transcriptional regulation of the human Spl gene by Ets-1 and found that the gene expression and promoter activity of Sp1 are regulated by Ets-1 in cancer cells. Functional analyses of two Ets-1-binding sites in the Sp1 gene promoter showed that only Ets-1-binding site -413 to -404 is involved in the activation of the gene by Ets-1. These results indicate that Ets-1 enhances expression of the beta-1,4-GaIT V gene through activation of the Sp1 gene in cancer cells.